top of page

March 2021 // Science

Updated: Oct 26, 2021

We are excited to share a scientific publication about the beneficial effect of the prototype SERI WOBE437 in a clinically relevant mouse model of Multiple Sclerosis and transient spasticity.


The article is published on ACS Pharmacology & Translational Science as the result of collaborative work between the group of Prof. J. Gertsch and Prof. B. Engelhardt at the University of Bern under the leadership of Dr. Andrea Chicca.


Find out more https://pubs.acs.org/doi/10.1021/acsptsci.0c00214



Graphic: Reynoso-Moreno et al., 2021.

Recent Posts

See All

January 2024 // Company & Communication

Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510. Synendos transitions to a clinical-stage biotech company developing innovative Endocanna

July 2023 // Communication

Synendos Therapeutics AG announces that co-founder and Scientific Advisor Board member, Professor Jürg Gertsch, presented groundbreaking new findings on an endocannabinoid transporter at the 10th Gord

Comments


bottom of page